Gabapentin Capsule
Product Images NDC 60687-580

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60687-580). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg Gabapentin Capsule Blister (100 mg Blister)

A label sheet for Gabapentin capsules, USP 100 mg strength, from American Health Packaging. Each label includes the drug name, dosage form as capsule, strength of 100 mg, a barcode, and placeholders for lot number and expiration date. The labels are arranged in multiple identical rows and columns on the sheet.*

FDA Label Image

Ahp58001

Gabapentin 300 mg oral capsule shown in two views. The capsule is white and imprinted with the code '216' in blue on one half. No additional markings or branding are visible on the capsule surface.*

FDA Label Image

Ahp59101

Gabapentin 100 mg oral capsules are yellow, hard gelatin capsules. One side is printed with the imprint '215' in blue. The capsules have a smooth, glossy finish and show a clear capsule seam.*

FDA Label Image

Ahp60201

Gabapentin 300 mg oral capsule shown as an oblong, orange capsule with the imprint '214' on one side. The image displays two views of the capsule against a gray measurement grid background. The labeler is American Health Packaging.*

FDA Label Image

Cockcroft And Gault Equation (Equation)

A formula calculating creatinine clearance (CLCr) is shown, involving age, weight, serum creatinine, and a factor for female patients. This text panel provides a medical equation related to renal function assessment, but does not include specific drug dosing or usage information.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Figure1)

A line graph showing mean pain score over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks including baseline; the y-axis shows mean pain score from 0 to 10. The graph is divided into a 4-week dose titration period and a 4-week fixed dose period, with gabapentin showing decreasing pain scores over time compared to stable scores in placebo.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Figure2)

A line graph comparing mean pain scores over seven weeks among three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents time in weeks, subdivided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows the mean pain score scale from 0 to 10. Both Gabapentin doses show a reduction in pain scores compared to placebo.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥ 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Figure3)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing response rates in two studies. Study 1 shows response rates for placebo (PBO) at 12% and Gabapentin 3600 mg (GBP 3600) at 29%. Study 2 shows placebo at 14%, Gabapentin 1800 mg at 32%, and Gabapentin 2400 mg at 34%. Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥ 12 Years Of Age With Partial Seizures (Figure4)

A scatter plot graph showing the relationship between daily dose (mg) on the x-axis and difference (%) on the y-axis for three studies labeled a, b, and c. Each study is represented by distinct markers (black square for study a, grey square for study b, and open square for study c) at various dose levels ranging from 600 mg to 1800 mg.*

FDA Label Image

Structural Formula (Structure)

Chemical structure diagram of gabapentin showing a cyclohexane ring with two substituents: an aminomethyl group (CH2NH2) and an acetic acid group (CH2CO2H).*

FDA Label Image

Image 01

Gabapentin 100 mg capsules label from American Health Packaging. The label states the product is USP grade, prescription only, with a package size of 100 capsules (10 x 10). Storage instructions and warnings about child safety and product integrity are included. The label also references Ascend Laboratories, LLC as the source of the drug product.*

FDA Label Image

Image 03

Gabapentin Capsules USP 300 mg label displaying two identical panels for 100 capsules (10 x 10) from American Health Packaging. The label shows dosage strength, NDC number 60687-591-01, barcode, pharmacist instructions for dispensing with medication guide, and storage and usage information.*

FDA Label Image

Image 04

Gabapentin capsule labels, USP 300 mg strength, printed by American Health Packaging, Columbus, Ohio. Each label includes product name, strength, a barcode, spaces for lot number and expiry date, and manufacturer information. The labels are arranged in pairs on a single sheet.*

FDA Label Image

Image 05

Gabapentin 400 mg capsules, USP, in a package of 100 capsules (10 x 10) labeled for prescription use only. The label includes the NDC 60687-602-01 and instructions for pharmacists to dispense the medication guide with the product. Storage and usage information is provided, indicating temperature guidelines and child safety warnings. Distributed by American Health Packaging, Columbus, Ohio.*

FDA Label Image

Image 06

Label sheet containing multiple identical labels for Gabapentin Capsule USP 400 mg, produced by American Health Packaging. Each label shows the product name, strength, dosage form, a barcode, placeholders for expiry and lot numbers, and the manufacturer location in Columbus, Ohio.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.